Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026EP EuropaceOpen Access

S-ICD in genetic arrhythmias is linked to a ~21% device-related complication rate over 7.7 years.

View Full Paper
Ask AI
Bookmark
Share

Population

201 consecutive patients with genetic cardiac arrhythmias who underwent index S-ICD implantation, mean age…

Design

Cohort

Follow-up

7.7 (3.8–12.0) years

Key result

Subcutaneous implantable cardioverter-defibrillator implantation in patients with genetic cardiac arrhythmias was associated with a 20.9% rate of device-related complications over 7.7 years.

Authors

YMY MatsudaKKK M KooimanAWA De Weger

Discussion

Loading...

Member takes

Overview

May suggest lower arrhythmic risk with DPP6 mutation; hypothesis-generating and should not yet change practice.

Key Points

  • The aim was to investigate long-term outcomes of S-ICD implantation in patients with genetic cardiac arrhythmias.
  • 201 patients who underwent S-ICD implantation were retrospectively enrolled between Feb 2009 and Sep 2024.
  • Endpoints included device-related complications and occurrence of ventricular tachyarrhythmia.
  • Multivariate analysis was used to identify predictors of complications and therapy outcomes.
  • 3.5% of patients died during a mean follow-up of 7.7 years.
  • Device-related complications occurred in 20.9% of patients, with no significant difference across genetic types.
  • Ventricular tachyarrhythmia was observed in 18.9% of patients and varied significantly among genetic disease types (p<0.01).

Study Design

Type

Cohort (n=201)

Multicenter

No

Structured PICO

P
Population
201 patients (mean age 40 years) with genetic cardiac arrhythmias who underwent index S-ICD implantation, followed for a median of 7.7 years.
E
Exposure
Subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation
O
Outcome
Device-related complications, ventricular tachyarrhythmia (composite of appropriate therapy and ventricular tachycardia without therapy), and inappropriate therapy after index S-ICD implantationcomposite

In patients with genetic cardiac arrhythmias, long-term S-ICD outcomes show similar device-related complication rates across disease types, but significant differences in the incidence of ventricular tachyarrhythmias and inappropriate therapy.

Cite This Study

Matsuda et al. (2026) conducted a cohort in genetic cardiac arrhythmias (n=201). Subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation was evaluated on Device-related complications, ventricular tachyarrhythmia, and inappropriate therapy. Subcutaneous implantable cardioverter-defibrillator implantation in patients with genetic cardiac arrhythmias was associated with a 20.9% rate of device-related complications over 7.7 years.

synapsesocial.com/papers/6a3f97a5125782b61d865812https://doi.org/10.1093/europace/euag105.1140
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of the subcutaneous implantable cardioverter defibrillator2026
  2. 2Predictors of recurrent ventricular arrhythmias and the impact of genetic testing in a hypertrophic cardiomyopathy patient cohort at long term follow up2026
  3. 3Dutch outcome in implantable cardioverter-defibrillator therapy extended follow up do it xl long term outcomes in a large primary prevention population2026
  4. 4Early complications and long-term outcomes of patients treated with a subcutaneous cardioverter-defibrillator: temporal trends and clinical implications of the anaesthetic strategies adopted at implant2026
  5. 5Subcutaneous ICD therapy in patients with monomorphic ventricular tachycardia: arrhythmia recurrence, shock burden, and management strategies2026